HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHA labeling

This article was originally published in The Rose Sheet

Executive Summary

Access Business Group urges FDA to exempt alpha hydroxy acid-containing cosmetics from proposed "sunburn alert" labeling if they demonstrate no increased likelihood of sun sensitivity. Division of Alticor, which markets cosmetics and toiletries under the Artistry and Alticor brand names via Amway and e-commerce venture Quixtar, Access Business Group submitted study results demonstrating that "properly formulated product can show no statistical difference in sun sensitivity from untreated skin." Study results, first presented at American Academy of Dermatology meeting in 1999, demonstrate mean erythema scores for sites treated with 3.3%-5% lactic acid and pH ranging from 4-4.5 were not significantly different from irradiated untreated control sites and control site abraded with loofah sponge. CTFA has recommended cosmetics formulated with 1% AHAs be exempted (1"The Rose Sheet" Feb. 10, 2003, p. 3)...

You may also be interested in...

AHA Labeling Exemptions, Minimum Threshold Urged By CTFA

Alpha hydroxy acid "sunburn alert" labeling requirements should not apply to certain products depending on their use or if they fall below a specific AHA concentration threshold, the Cosmetic, Toiletry and Fragrance Association maintains in Jan. 31 comments to FDA

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts